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Background: Sequential chemo-radiotherapies with intensive radiation components deliver promising results in
non-resected non-small cell lung cancer (NSCLC). In general, radiation doses are determined by dose constraints for
normal tissues, not by features relevant for tumor control. DART-bid targets directly the doses required for tumor
control, correlating doses to tumor volume in a differentiated mode.
Materials/Methods: Radiation doses to primary tumors were aligned along increasing tumor size within 4 groups
(<2.5 cm/2.5–4.5 cm/4.5–6.0 cm/>6.0 cm; mean number of three perpendicular diameters). ICRU-doses of 73.8 Gy/
79.2 Gy/84.6 Gy/90.0 Gy, respectively, were applied. Macroscopically involved nodes were treated with a median
dose of 59.4 Gy, nodal sites about 6 cm cranial to involved nodes electively with 45 Gy. Fractional doses were
1.8 Gy twice daily (bid).
2 cycles chemotherapy were given before radiotherapy.
Between 2004 and 2009, 160 not selected patients with 164 histologically/cytologically proven NSCLC were
enrolled; Stage I: 38 patients; II: 6 pts.; IIIA: 69 pts.; IIIB: 47 pts. Weight loss >5%/3 months: 38 patients (24%).
Primary endpoints are local and regional tumor control rates at 2 years (as >90% of locoregional failures occur
within 2 years). Secondary endpoints are survival and toxicity. With a minimum follow-up time of 2 years for
patients alive, the final results are presented.
Results: 32 local and 10 regional recurrences occurred. The local and regional tumor control rates at 2 years are
77% and 93%, respectively.
The median overall survival (OS) time is 28.0 months, the 2- and 5-year OS rates are 57% and 19%, respectively. For
stage III patients, median OS amounts to 24.3 months, 2- /5-year OS rates to 51% and 18%, respectively.
2 treatment-related deaths (progressive pulmonary fibrosis) occurred in patients with pre-existing pulmonary
fibrosis. Further acute and late toxicity was mild.
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Conclusions: This novel approach yields a high level of locoregional tumor control and survival times. In general it
is well tolerated. In all outcome parameters it seems to compare favourably with simultaneous chemo-
radiotherapies, at present considered ‘state of the art’; and is additionally amenable for an unselected patient
population.
Keywords: Lung cancer, Non-small cell lung cancer, Accelerated radiotherapy, Conformal radiotherapy, Target
splitting, Prospective clinical trials, Combined modality, Treatment time, Accelerated repopulation, DART-bidIntroduction
Lung cancer is the most commonly found malignant dis-
ease worldwide, and the leading cause of death due to can-
cer. About 80 percent of lung cancer patients are affected
by tumors with non-small cell histologies (NSCLC); and
30–40% of them at diagnosis have locoregionally limited,
but-for tumor extension or medical reasons-inoperable dis-
eases in stages I–III.
For stage I patients increasingly a stereotactic approach
is chosen, whereas for locoregionally advanced stages
more fractionated forms of radiotherapy are the corner-
stone of treatments, often combined with chemotherapy.
State of the art treatments for locoregionally advanced
NSCLC comprise 60 Gy simultaneously applied to 2 cycles
of chemotherapy. However, for toxicity reasons this
approach is amenable only for about 30% of patients [1].
Furthermore, the premature closure of RTOG 0617
randomizing 60 Gy vs. 74 Gy suggests, that improvement
of the results by intensifying radiation is improbable [2].
In contrast, sequential chemo-radiotherapeutic modal-
ities seem to offer promising possibilities. A positive dose-
response relationship in the range 60–100 Gy has been
established for tumor control and survival [3]; and there is
growing evidence that shortening of the overall treatment
time is crucial [4,5]. However, until now radiation doses in
escalation trials are always determined by dose constraints
for normal tissues, not by features of tumors relevant for
tumor control [3,6,7]. As a consequence, larger tumors in
these trials are often treated with smaller doses than small
tumors.
Recently, in our clinic the conformal target splitting
technique has been developed for treating lung cancer,
attended by a concept of rather tight margins in the treat-
ment planning process [8-11]. Initially, high dose radiation
therapies with conventional fractionation rendered encour-
aging results [12]. Thereafter, in order to lower treatment
times, in a phase I/II trial up to 90 Gy to primary tumors
and 63 Gy to nodes in 1.8 Gy bid fractions were applied,
preceded by 2 cycles chemotherapy [13]. The results
showed good tolerability and promising results for tumor
control and survival. The here presented consecutive trial
targets directly the doses required for tumor control in a
differentiated mode. Radiation doses were related to tumor
volume, treating larger tumors with higher doses. Primaryendpoints are the local and regional tumor control
rates at 2 years (as >90% of locoregional failures occur
within 2 years). Secondary endpoints are survival and
toxicity. With a minimum follow-up time of 2 years for




Eligible were patients with nonresected, histologically/
cytologically proven NSCLC in stages I through III B,
and a Karnofsky Index =>60.
Radiotherapy had to be given twice daily with fractional
doses of 1.8 Gy (ICRU Report 50), an interval of >10 h, at
5 days/week. Overall doses to the primary tumors were
aligned along increasing tumor size within 4 groups in the
range 73.8–90.0 Gy (Tables 1 and 2). The dose to macro-
scopically involved nodes had to be 54.0–72.0 Gy (adapted
to the degree of extent and invasion, left to the discretion
of the treating physician), to elective nodes 45.0 Gy within
a region of about 6 cm cranial to macroscopically involved
nodes. In stage I patients elective nodal irradiation could
have been omitted.
The number of cycles of induction chemotherapy was
left to the discretion of the referring department; preferably
it should have been limited to two cycles. The interval be-
tween chemotherapy and radiotherapy should have been <
8 days. Simultaneous chemotherapy was not allowed.
Staging procedures
Staging evaluations included a medical history, physical
examination, chest X-ray, bronchoscopy, 18-fluorodeoxy-
glucose-positron emission tomography (FTG-PET) and a
CT-scan or MRI of the brain.
Radiotherapy planning and delivery
Patients were set up in vacuum cradles, usually supine
with the hands above the head. Planning CTs in treat-
ment position were performed as ‘slow CTs’, with pa-
tients freely breathing (non-spiral CT; 4 s/slice; slice
thickness 7 mm) or in a few patients as 4D-CT/average
projection at the end of the accrual period (internal tar-
get volume concept, grossly summarizing and depicting
the different positions of the moving tumor, rendering
Table 1 Patient (n = 160) and tumor (n = 164)
characteristics
Age, years, median 66 (44–87)
Gender: m/f, n 119/41
Weightloss >5%/3 month, n (%) 38 (24)





Squamous cell carcinoma 104 (63)
Adenocarcinoma 43 (26)




III A 69 (43)
III B 47(29)
Affiliation according PT-Ø, n (%)
Group 1 (< 2.5 cm) 27 (17)
Group 2 (2.5–4.5 cm) 94 (57)
Group 3 (4.5–6.0 cm) 30 (18)
Group 4 (> 6.0 cm) 13 (8)
Gross tumor volume (ccm, median/mean, range)
Group 1 17/33 (2–167)
Group 2 50/68 (9–492)
Group 3 92/108 (50–205)
Group 4 163/238 (105–572)
Tumor localisation, n (%)
Central 44 (27)
Peripheral 120 (73)
Abbreviations: NSC-n.o.s. = Non small cell-not otherwise specified;
AJCC = American Joint Commission on Cancer, PT-Ø = Primary tumor diameter
(mean number of 3 perpendicular diameters).







Nodes (median, range) 59.4 (54.0–73.8)
Nodes electively* 45.0
Fractional dose (Gy) 1.8 bid
Interval >10 h
Treatment duration (days, median, range) 33 (29–42)
Chemotherapy before radiotherapy (patients, %) 106 (66)
Cycles (n, range) 2 (1–6)
* to sites about 6 cm cranial to macroscopically involved nodes.
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margin of 7 mm was added to the gross tumor volume
(GTV) to draw the planning target volume (PTV). In gen-
eral, pretherapeutic PET-CT scans were visually studied
by the treating physician before drawing the PTV; only in
cases of atelectasis a second, postchemotherapeutic PET-
CT was performed and PET- and planning-CT scans were
digitally matched. In patients receiving chemotherapy, the
PTV was delineated at the postchemotherapy scans. PTVs
of primary tumors and lymph nodes were drawn within
the lung window and soft tissue window, respectively.
For patients with locoregionally advanced disease mostly
the conformal target splitting technique was used [8,9].
Treatment plans were generated in a ‘forward’ plan-
ning process, minimizing especially radiation to healthylung tissues, irrespective of its level or volume. In gen-
eral the following lung dose constraints were applied:
V20 (volume receiving >20 Gy) for a single lung 50%,
V25 for both lungs 30%; in some patients these
constraints were surpassed. A dose constraint for spinal
cord was set at 45 Gy; and for esophagus at 80 Gy (mea-
sured in the center of the esophagus at its most exposed
level). Examples of treatment plans have been published
recently [9].
Treatments were applied by 15 MV photons.
The set-up of patients was adjusted in 3 dimensions
before every treatment, matching anatomical structures
as esophagus, trachea, main bronchi by means of two
kv-images in two dimensions [14].
Medicinal agents
Chemotherapeutically, in general cisplatin or carboplatin
containing doublets were used.
If parts of the esophagus were within or near the PTV,
an antimycotic prophylaxis was given (Amphotericine B
lozengers, 4 times daily, during the full course of radio-
therapy) [15,16].
Follow-up procedures
Patients were seen for assessment of toxicity and tumor
control 6 and 12 weeks after the end of radiotherapy,
then every 3 months for the first year, every 4 months
during the second and third year, hence every six
months. At the first control a chest X-ray, at all other
controls thoracic CT-scans were performed. Local or
regional tumor progression was diagnosed, if there was
an increase in tumor volume compared with the previ-
ous CT-scan. In case of doubt a FDG-PET had to be
performed.
Acute and late toxicity was scored according to the
RTOG/EORTC criteria except for pulmonary toxicity
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cough or dyspnea on exertion’ is common in these
pulmonary compromised patients. As in our experience
in rare cases pneumonitis as an acute side effect can be
present until 6 months after therapy, toxicity is consid-
ered late if it persisted or developed beyond 6 months
after the completion of radiotherapy.
Statistical analysis
Overall survival and local tumor control rates were calcu-
lated using the Kaplan-Meier method. All time intervals
refer to the start of therapy, induction chemotherapy
included. The median follow up time for all patients is
26.0 months (3.8–96), for survivors 38.1 months (24.8–
96 months). No patient has been lost to follow-up.
In order to collect sufficient data in the four treatment
groups, it was prospectively determined to enrol at least
150 patients in this trial.
The study was performed with consent of the medical
ethics committee of the province Salzburg. All patients
gave informed consent.
Results
Patient and treatment parameters
From January 2004 until December 2009 160 patients
with 164 histologically/cytologically proven NSCLC were
enrolled. This corresponds to 96% of all NSCLC patients
in stages I–IIIB referred to our department in this period
(patients with malignant pleural effusions, pancoast
tumors and one patient with pulmonal fibrosis excluded,
see below). Five of the 7 patients not enrolled presented
with KI <60%, two patients refused to be treated twice
daily for geographical reasons. Hence we consider the
study population as continuously referred and unselected.
Patient and tumor characteristics are shown in Table 1.
Notably, 24% presented with >5% weight loss during
the three months preceding diagnosis; and 51% had a
KI <80%.
Treatment parameters can be seen in Table 2. All but
five primary tumors received the dose corresponding to
the respective treatment group (in 3 patients of group 2
and in 2 patients of group 3, doses were lowered for 3
fractions; for dose/volume issues or a reduced general
status of the patients). The vast majority of stage II/III
patients received an elective nodal treatment cranial to
macroscopically involved sites. For dose-volume reasons
in 18 patients (15%) this elective treatment was not
performed.
Local and regional tumor control, distant failures
We observed 32 local failures, 30 of them occurred
within 2 years; this results in an actual 2- and actuarial
5-year local tumor control rate of 77% and 74%, respect-
ively (Figure 1a). The distribution of local recurrenceswithin the four groups can be seen in Figure 1b. The
best results show the patients in group 1 (90% tumor
control at 2 years), the control rates in group 2 to 4 are
similar and lie between 65% and 76%/2 years.
10 patients showed an isolated regional failure (with-
out a local recurrence) at a median time of 14 months
(range 8–26 months), corresponding to a regional con-
trol rate of 93% at 2 years (Figure 1c). Five of these failed
at distant sites simultaneously. In 6 patients the regional
failure was located in originally irradiated sites (54.0–
63.0 Gy), in 4 patients in non-treated regions (three of
these four patients belong to the small group of 18
patients, where an elective nodal treatment primarily
was omitted).
In 57 patients (36%) hematogenous metastases
appeared during the course of the disease, mostly in the
brain (23 patients).
Overall survival
The actual overall 2 year-survival rate for all patients and
the actuarial 5 year-survival rate is 57% and 19%, respect-
ively, the median survival time 28.0 months (Figure 2a).
The overall median and 5 year-survival rate for patients in
stage I, II, IIIA, IIIB, IIIA + B amounts to 43.4, 33.1, 22.0,
27.8, 24.3 months and to 22%, 33%, 22%, 11%, 18%, re-
spectively (Figures 2b). Survival curves according to tumor
size groups are depicted in Figure 2c.
30 patients died from intercurrent diseases at a median
time of 15.3 months (range 3.8–72.1 months). Nine of
them have had stage I tumors and were referred to
primary RT due to a low performance status.
Toxicity
Table 3 shows the non-hematologic toxicities. In two
patients a treatment-related death occurred: progressive
pulmonary fibrosis (not pneumonitis) 5 and 6 months
after the end of radiotherapy. The patients were treated
for stage IIIA tumors, with unexceptional pulmonary
doses (V25 30% and 23%, respectively). In the
pretherapeutic CT scans of both patients clear radiologic
signs of existing pulmonary fibrosis were visible. These
events occurred within 2 months during the second year
of the accrual period. Thereafter patients with pulmonary
fibrosis were excluded from enrolment in this trial. Apart
from that, treatments were well tolerated.
One patient showed late esophageal toxicity grade 3
(stenosis, 7 months after the end of radiotherapy with
moderate esophageal doses, treated by stenting; a few
months later the patient died for a local recurrence).
Almost all patients present slight to moderate
posttherapeutic densities in the lung parenchyma, which
did not cause symptoms > grade 2.
Four patients died from a pulmonary hemorrhage. In
three of them a recurring central tumor was diagnosed
ba
c
Figure 1 Kaplan-Maier plots for a) local tumor control all tumors; b) local tumor control by tumor size groups; c) regional tumor
control all patients.
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central tumor with close proximity to the bronchial
arteries for about 4 cm, died 6.5 months after finishing
radiotherapy. The autopsy demonstrated a leakage of a
bronchial artery without detection of a recurrent tumor,
nor necrotic tissue. The most probable cause of death of
this patient is a brochoarterial fistula arisen after retrac-
tion of the central, infiltrating tumor.
Discussion
We consider the concept and mode of implementation of
DART-bid a novel approach for treating non-resectedNSCLC. Usually in dose escalation protocols, for reasons
of tolerability, doses are determined by dose constraints for
normal tissues, not by features relevant for tumor control
as e.g. tumor size [3,6,7,17-19]. As a consequence large tu-
mors are often treated with smaller doses than small tu-
mors and presumably high volume tumors are occasionally
excluded from enrolment in protocols. DART-bid targets
straightforward the doses required for a high level of tumor
control. New is also the differentiation of doses on tumor
sites: it is sufficient to treat nodes with lower doses com-
pared to primary tumors, because generally nodes are well
oxygenized, without necrotic areas and of smaller size.
ab
c
Figure 2 Overall survival. Kaplan-Maier plots for a) all patients; b) patients by tumor stage; c) patients by tumor size groups.
Table 3 Acute (A) and late (B) non-hematologic toxicity
according to EORTC/RTOG criteria, n (%)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
A Esophagus 51 (32) 16 (10) 7 (4) - -
Lung NA 10 (7) 6 (4) - 2 (1)
B Esophagus - - 1 (1) - -
Lung NA 15 (9) - - -
Abbreviations: EORTC/RTOG = European Organisation for Research and
Treatment of Cancer/Radiation Therapy Oncology Group.; NA = not assessed.
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favourably with the outcome of other modalities in all
endpoints: local and regional tumor control, survival,
toxicity.
Local tumor control
In reported studies of simultaneous radio-/chemotherapies
and dose escalation protocols locoregional tumor control
is mostly not appropriately examined [1,3,6,20,21]. Corre-
sponding diagnostic methods and intervals are not pro-
spectively performed. Often only the patterns of first
relapses are reported. Simultaneous radio-/chemotherapies
Table 4 Selected trials in the treatment of NSCLC






rate at 2 y.:
Local/locoreg.
Overall survival
Median (mo) 2/5 y (%)
A Curran et al. [1] 195 II, III good PS 2 × Ch, sequ 60 Gy 4 NR 14.6 -/10
195 II, III good PS 2 × Ch, sim 60 Gy 23 NR 17 (p = 0.046) -/16
187 II, III good PS 2 × Ch, sim 69.6 Gy/
1.2 Gy bid
45 NR 16 -/13
Furuse et al. [20] 158 III — 2 × Ch, sequ 56 Gy 2 NR 13.3 27/9
156 III — 2 × Ch, sim 56 Gy
split course
3 NR 16.5 (p = 0.04) 35/16
Fournel et al. [21] 101 III good PS 3 × Ch, sequ 66 Gy 3 NR 14.5 26/14(4y)
100 III good PS 2 × Ch, sim 66 Gy,
plus 2 × Ch.
32 NR 16.3 (p = 0,24) 39/21(4y)
B Stinchcombe et al. [25] 62 III good PS, V20 < 35% Ind Ch 2×,
60–74 Gy sim Ch
8 NR 25 -/27
Bradley et al. [26] 53 I–III good PS, V20 < 30% 74 Gy, sim Ch
weekly
12 NR 25.9 NR
C Kong et al. [3] 106 I–III unselected, long
accrual period
63–102.9 Gy/2.1 Gy/
6–10w.; 19% ind Ch
2×
7 -/40 19.0 37/13
Bradley et al. [6] 177 I–III 44% stage I, V20 <37% 70.9–90.3 Gy/
2.15 Gy/6.5–8,5 w.;
14% ind Ch
3 — NR NR




0 -/49 19.6 39/11
D Van Baardwijk et al. [7] 166 I–III unselected 64.8 Gy (50.5–79.2)/
1.8 Gy bid, i = 8 h/
4.5 w.; 55% ind.
Ch 3×
5 NR 21.0 45/–
Saunders et al. [31] 225 I–III good PS 60 Gy/2 Gy/6 weeks 3 NR 13 21/NR
338 I–III good PS 54 Gy/1.5 Gy tid/
12d/i≥ 6 h
19 NR 16.5 (p = 0.008) 30/NR
Wurstbauer et al. [13] 30 I–III unselected 84.6 Gy primary t.,
63 Gy nodes/1.8 Gy
bid, i >10 h/5 w.;
63% ind. Ch 2×
7 –/61 27.7 63/23
Current study 160 I–III unselected 73.8–90.0 Gy
primary t., 59.4 Gy
nodes/1.8 Gy bid,
i >10 h/5 w.; 66%
ind. Ch 2×




A. Randomized studies comparing sequential versus simultaneous radio-/chemotherapy. B. Further simultaneous studies. C. Radiation dose escalation trials. D.
Trials employing accelerated radiotherapy.
Abbreviations: NR = not reported; Ch = chemotherapy; sequ = sequential, sim = simultaneous, ind = induction, PS = Performance status.
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30–40% of the patients [1,20,21], sequential high-dose
treatments with conventional fractionation in about 40–
50% [12,22].
Total dose levels in our protocol were set with the
intention of a high degree of tumor control, according
to our experience in the preceding phase I/II trial [13].
A control rate of 90% for the small tumors (group 1)and between 65% and 76% for the larger ones (group 2–4)
seems to be impressive, although there is still space for
improvement. In our patients, image guidance was
performed in every fraction, matching anatomical struc-
tures as trachea, main bronchi, esophagus via two orthog-
onal kv-images. Recently, in a series of 30 patients we
compared the topographic accuracy matching anatomical
structures as described versus matching on gold fiducials,
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tumor. In 8 out of 30 patients (27%) in >30% of fractions
the vector of the position corrected via fiducials exceeded
7 mm, which is our commonly used margin from GTV to
PTV. In other words, without position correction along
fiducials, in a quarter of the patients in more than a third
of the fractions parts of the GTV come to lie outside the
treated volume. Hence, a further improvement of local
control might not primarily be a matter of raising the total
dose, but of raising geographic accuracy. Therefore, in our
successive series of NSCLC patients, tending to further
improve local tumor control, total doses remain un-
changed and IGRT with gold fiducials (or cone beam CT)
is performed routinely.
It has been discussed, if local tumor control should be
adjudged only if tumors initially respond with a partial
or complete response radiologically (RECIST-criteria)
[23]. We cannot share this opinion, because occasionally
we observed lung tumors presenting at CT-controls as
opacities in dimensions of a minor response for periods
longer than 10 years.
Regional tumor control
The regional tumor control rate of 93% in our study is
high and confirms the concept to apply lower doses to
nodes in comparison to primary tumors.
Regarding elective nodal irradiation, in four patients
an isolated nodal recurrence in previously untreated
sites occurred. Only one of these patients belong to the
group of 104 stage II/III patients treated primarily elec-
tively cranial to macroscopically involved nodes, whereas
three belong to the small group of 18 patients, in which
an elective nodal irradiation was postponed for volume
issues. This confirms the necessity of elective nodal radi-
ation cranial to involved nodes. In general nowadays,
elective nodal irradiation has been abandoned, in order
to gain potential to raise the dose to macroscopic tumor;
but series conducted in this way report isolated elective
nodal recurrences in up to 9% of the patients [6,24].
Survival
A median overall survival time of 28.0 months for all pa-
tients and 24.3 months for stage III patients compares
favourably with the results of other approaches (Table 4).
Simultaneous chemo-/radiotherapies result in survival
times of about 17 months [1,20,21] (Table 4). The pa-
tients in these studies were not PET staged and therefore
an imbalance for stage migration may occur; however, in
contrast to our unselected population, these patients
were in good general condition, without considerable
comorbidities and without weight loss. There are simul-
taneous treatments applying 74 Gy, achieving survival
times up to 26 months; in these series the additional
selection criterion of a relatively strict V20 of 30–35% isused, most probably a surrogate for patients with lower
‘tumor load’ [25,26].
Toxicity
Except the two patients with pre-existing pulmonary
fibrosis (see above), treatments were tolerated very well.
We attribute the good tolerability and the fact, that 97%
of the primary tumors could have been treated with the
dose of the respective group, to three reasons: the beam
arrangements inherent to the target splitting technique,
the use of rather tight margins and the differentiation of
doses [8-10]. These issues have been discussed in detail
in the report of the preceding phase I/II trial [13].
Briefly, target splitting is a technique with a high poten-
tial of sparing organs at risk. Concerning the tight mar-
gin of only 7 mm from GTV to PTV: the internal target
volume concept, using slow planning CTs or average
mode 4D planning CTs, averts the necessity of adding a
general extra margin for tumor motion (internal mar-
gin). And, as in stereotactic radiotherapy, we consider a
margin for microscopic spread from GTV to a clinical
target volume (CTV) in high dose radiotherapy dispens-
able, because a sufficient dose to the rim of microscopic
disease (about 45 Gy in 2,5 weeks) is delivered anyway.
Simultaneous vs. sequential therapies with intensified
radiation component
At present simultaneous chemo-/radiotherapies are con-
sidered state of the art for locoregionally advanced
NSCLC. Several randomized trials have proven an ad-
vantage of 60 Gy applied simultaneously vs. sequentially
[1,20,21]. The radiosensitizing chemotherapeutic effect
improves the local tumor control, median overall sur-
vival times raise from about 14 to 17 months. As also
side effects act simultaneously, these therapies are more
toxic; therefore only about 30% of stage III patients are
amenable for this approach [1]. A further, grave draw-
back of the simultaneous approach is the lack of
improvements raising radiation doses. RTOG 0617, ran-
domizing 60 Gy vs. 74 Gy recently was closed prema-
turely. An interim analysis showed that 74 Gy could not
produce a survival benefit and possibly give worse
results [2]. Final analysis must be expected, but 60 Gy,
applied with 3D-conformal and IMRT techniques, seem
to be the upper dose limit in simultaneous radio-
/chemotherapies.
In contrast, sequential therapies with intensified radi-
ation components may offer promising developments.
The potential of 2 cycles induction chemotherapy to
eradicate peripheral micrometastases, thus lowering the
incidence of later distant relapse, has been proven in tri-
als [27,28] (and often induction chemotherapies also
provide an advantegous shrinkage of tumors before
starting radiotherapy). However, as discussd in detail in
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cells between cycles of chemotherapy and during the
interval between chemotherapy and radiotherapy might
occur [13,29,30].To prevent this, we avoid to apply more
than 2 cycles chemotherapy, and try to keep the interval
to radiotherapy <8 days.
Similarly, a short overall radiation treatment time is
crucial [5]. Fowler estimates a loss of local tumor control
of 11% per week for treatment times beyond 4 weeks
[4].This reflects the drawback of dose escalation proto-
cols performed with conventional fractionation [3,6,12]
(Table 4). One way to lower radiation treatment time is
treating patients more often than once daily [7,13,31]
(Table 4). Van Baardwijk et al. report on 1.8 Gy bid
treatments with an individualized prescription based on
normal tissue dose constraints (19 Gy mean lung dose)
[7]. A median dose of 64.8 Gy (range 50.4–79.2 Gy) was
applied and a median overall survival time of 21.0 -
months was achieved. Equal doses to primary tumors
and nodes were given. Treatments were safe, figures for
locoregional tumor control are not reported. DART-bid
enables the application of higher doses; and regarding
the low toxicity, these doses could even be raised, if ne-
cessary. The latter is investigated in ongoing studies, in
the mode described above.
Another method to lower treatment times is
hypofractionation. Mature result of such regimes are not
yet available. Substantial side effects, especially concerning
central tumors, could be an issue in this setting.Conclusions
DART-bid following induction chemotherapy yields a high
level of locoregional tumor control and survival times. In
general it is well tolerated. In all outcome parameters it
seems to compare favourably with simultaneous chemo-
radiotherapies, while being additionally amenable for an
unselected patient population.Competing interests
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